AHA 2021: EMPEROR-Preserved: Empagliflozin, Health Status, & QoL in Patients With HFpEF | Dr Butler

Подробнее о видео

Watch the full video on Radcliffe Cardiology here:

In this short interview, Dr Javed Butler (University of Mississippi Medical Center, Jackson, MS, US) discusses the findings of an analysis from the EMPEROR Preserved trial. In EMPEROR-Preserved, empagliflozin treatment was associated with reduction in the risk of the primary endpoint of CV death or HF hospitalization in patients with HFpEF. In this analysis, presented at AHA 2021, the investigators assessed whether the observed clinical benefits of empagliflozin varied by baseline health status and looked into the impact of the drug on health status outcomes.

Discussion Points:
-Rationale for the Study
-Health Status
-Design and Patient Population
-Key Findings
-Take-home Messages
-Next Steps

Recorded remotely from Jackson, 2021.

Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.